These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25871618)

  • 1. NKX6-1 Is a Novel Immunohistochemical Marker for Pancreatic and Duodenal Neuroendocrine Tumors.
    Tseng IC; Yeh MM; Yang CY; Jeng YM
    Am J Surg Pathol; 2015 Jun; 39(6):850-7. PubMed ID: 25871618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
    Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
    Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms.
    Chan ES; Alexander J; Swanson PE; Jain D; Yeh MM
    Am J Surg Pathol; 2012 May; 36(5):737-43. PubMed ID: 22498824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors.
    Barbareschi M; Roldo C; Zamboni G; Capelli P; Cavazza A; Macri E; Cangi MG; Chilosi M; Doglioni C
    Am J Surg Pathol; 2004 Sep; 28(9):1169-76. PubMed ID: 15316316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.
    Koo J; Mertens RB; Mirocha JM; Wang HL; Dhall D
    Mod Pathol; 2012 Jun; 25(6):893-901. PubMed ID: 22388755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical analysis of OTP and NKX6.1 in neuroendocrine tumors of the lung and pancreas.
    Yoxtheimer LM; Heymann JJ; Cohen C; Rao RA; Goyal A; Siddiqui MT
    Diagn Cytopathol; 2018 Dec; 46(12):1010-1014. PubMed ID: 30284410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cadherin 17 in well-differentiated neuroendocrine tumours.
    Snow AN; Mangray S; Lu S; Clubwala R; Li J; Resnick MB; Yakirevich E
    Histopathology; 2015 Jun; 66(7):1010-21. PubMed ID: 25388236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
    Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
    Long KB; Srivastava A; Hirsch MS; Hornick JL
    Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
    Soukup J; Manethova M; Stejskal V; Hornychova H; Cesak T; Netuka D; Ryska A; Gabalec F
    Endocr Pathol; 2023 Sep; 34(3):333-341. PubMed ID: 37552455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
    Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
    Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
    Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
    Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2.
    Hermann G; Konukiewitz B; Schmitt A; Perren A; Klöppel G
    Virchows Arch; 2011 Aug; 459(2):147-54. PubMed ID: 21739268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.
    Srivastava A; Hornick JL
    Am J Surg Pathol; 2009 Apr; 33(4):626-32. PubMed ID: 19065104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.
    Sangoi AR; Ohgami RS; Pai RK; Beck AH; McKenney JK; Pai RK
    Mod Pathol; 2011 Mar; 24(3):412-24. PubMed ID: 20890270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Positivity for SATB2 distinguishes Islet1 positive rectal neuroendocrine tumours from pancreaticoduodenal neuroendocrine tumours.
    Mohanty SK; Tiwari A; Bhardwaj N; Chuang F; Kim E; Lugo H; Yuan X; Diffalha SA; Peralta-Venturina M; Balzer B; Dhall D
    J Clin Pathol; 2021 Sep; 74(9):582-588. PubMed ID: 32934105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry.
    Bellizzi AM
    Adv Anat Pathol; 2013 Sep; 20(5):285-314. PubMed ID: 23939147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases.
    Graham RP; Shrestha B; Caron BL; Smyrk TC; Grogg KL; Lloyd RV; Zhang L
    Am J Surg Pathol; 2013 Mar; 37(3):399-405. PubMed ID: 23348208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duodeno-pancreatic neuroendocrine tumours.
    Peros G; Sakorafas GH; Konstantoudakis G; Giannopoulos GA; Petropoulou K; Parasi A
    Eur J Cancer Care (Engl); 2010 May; 19(3):393-402. PubMed ID: 19708940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of TTF1, CDX2 and ISL1 in 74 poorly differentiated neuroendocrine carcinomas.
    Lee H; Fu Z; Koo BH; Sheehan CE; Young GQ; Lin J; Patil DT; Yang Z
    Ann Diagn Pathol; 2018 Dec; 37():30-34. PubMed ID: 30236546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.